OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone240-813-1260
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.21 million
Profitability
Miscellaneous
Employees43
OptionableNot Optionable
OpGen (NASDAQ:OPGN) Frequently Asked Questions
What is OpGen's stock symbol?
OpGen trades on the NASDAQ under the ticker symbol "OPGN."
When did OpGen's stock split? How did OpGen's stock split work?
Shares of OpGen reverse split on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.
How were OpGen's earnings last quarter?
OpGen Inc (NASDAQ:OPGN) announced its quarterly earnings results on Thursday, August, 2nd. The medical research company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.60) by $0.03. The medical research company had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.79 million. OpGen had a negative net margin of 395.63% and a negative return on equity of 238.35%. View OpGen's Earnings History.
When is OpGen's next earnings date?
What price target have analysts set for OPGN?
1 brokers have issued 1 year price objectives for OpGen's shares. Their forecasts range from $6.00 to $6.00. On average, they expect OpGen's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 319.6% from the stock's current price. View Analyst Price Targets for OpGen.
What is the consensus analysts' recommendation for OpGen?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.
Has OpGen been receiving favorable news coverage?
News articles about OPGN stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OpGen earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of OpGen's key competitors?
Who are OpGen's key executives?
OpGen's management team includes the folowing people:
- Mr. Evan Jones, Chairman & CEO (Age 62)
- Mr. Timothy C. Dec, CFO, Principal Accounting Officer & Corp. Sec. (Age 60)
- Mr. Vadim Sapiro, Chief Information Officer (Age 48)
- Mr. Michael Farmer, VP of Marketing
- Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 60)
When did OpGen IPO?
(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.
Who are OpGen's major shareholders?
OpGen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.24%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.
Which major investors are buying OpGen stock?
OPGN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have bought OpGen stock in the last two years include Jven Capital, Llc and Timothy C Dec. View Insider Buying and Selling for OpGen.
How do I buy shares of OpGen?
Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OpGen's stock price today?
One share of OPGN stock can currently be purchased for approximately $1.43.
How big of a company is OpGen?
OpGen has a market capitalization of $12.36 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.
What is OpGen's official website?
How can I contact OpGen?
OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]
MarketBeat Community Rating for OpGen (NASDAQ OPGN)
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
